The QE2 Opens in Dubai
The Queen Elizabeth 2 (QE2) will open its doors to the public on the 18th of April 2018 following highly anticipated international interest.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416005377/en/
The Queen Elizabeth 2 opens as a floating hotel in Dubai (Photo: AETOSWire)
PCFC Hotels – part of the Dubai government’s Ports, Customs and Free Zones Corporation – has reinvented the legendary vessel as the latest must-see tourism destination, in a city renowned for its world-class attractions.
The world-famous cruise liner, which has a history spanning 5 decades, is now docked permanently at Mina Rashid, where her dining, accommodation and entertainment attractions will be unveiled. Her opening marks the first phase – a “soft opening” – of several stages in which segments of the liner will be opened and released for a unique experience capturing all that was grand about her forty years of service. In this first phase, she will be welcoming passengers on board to experience a selection of beautifully restored rooms and suites, to discover 5 of the planned 13 restaurants and bars and explore her rich history in the adjacent QE2 Heritage Exhibition.
Hamza Mustafa, CEO of PCFC Hotels commented: “To finally open the QE2 is a dream come true for my team and I. It is one of Dubai’s most highly anticipated projects and we know that a lot of people are going to be very excited to see her for the first time, or to step back on board the vessel that created so many wonderful memories during her 40 years at sea.
We are especially thankful to our Chairman, Sultan Ahmed Bin Sulayem whose vision and determination to give her a second life has come to fruition. His passion for the Queen Elizabeth 2 and all that she represents means that she can continue to deliver the grandeur that she stood for, within a new special location at the heart Mina Rashid, in Dubai.
We have dedicated more than 2.7 million man-hours into transforming this legendary ocean liner into the multi-faceted tourist destination that she is today and I am very proud to reintroduce her to the world as she embarks on the next stage of her celebrated journey. It has been an honor to work on this wonderful project and to help ensure that our lovely Lady lives up to her new slogan: still making history.”
The 13-deck hotel has been thoughtfully restored to her former glory – maintaining her most loved interior design features – including her period furniture, renowned paintings and famous memorabilia. The original porthole windows still add a maritime feel to the attractive modernized guest rooms and a number of her original restaurants have retained the same names and décor as her former years. Whilst extensively preserving her authentic elements, she has been fully equipped with all the latest technology.
Adjacent to the hotel lobby is the QE2 Exhibition – an interactive museum that showcases the QE2 during the 60’s when she was a pioneer in design, technology and lifestyle – words often used to describe the city she resides in today.
From small but beautifully designed ‘cabin’ style Standard Rooms starting at 17m², to the 76m² Royal Suites belonging to the Queen herself – the QE2 will offer a selection of 13 room and suite categories for Passengers to experience.
The gem in the crown of the QE2 are the two Royal Suites named after the Queen’s mother and grandmother. These suites offer a private veranda, conservatory and dining room – in addition to a luxurious bedroom. Highly personalised amenities are included for Passengers who can book the suite by invitation only.
During the soft launch of the QE2, Passengers can experience some of the ship’s original restaurants including The Chart Room – a sophisticated and historical lounge and bar; The Golden Lion – a traditional English pub and potentially one of Dubai’s oldest; The Pavilion – a family restaurant with an expansive terrace overlooking the marina; Lido – the hotel’s all-day-dining restaurant; The Grand Lounge – a cabaret-style lounge with a weekly entertainment programme; and the Yacht Club – a chic rendition of the former venue as well as a unique take on the traditional afternoon tea.
The hotel’s signature restaurant is The Queens Grill which offers a refined selection of British fine-dining dishes as well as a tasting menu that recreates a classic selection of dishes from 1969.
The QE2 is home to a number of unique event and meeting room spaces, most notably The Queen’s Room – an inimitable ballroom unlike any other in the city.
The grand launch of the QE2 will take place in October 2018.
Notes to Editor
Download a selection of images here: https://we.tl/UpFGMThloR
About PCFC Hotels
PCFC Hotels (PCFCH) is a wholly-owned subsidiary of the Government of Dubai’s Ports, Customs & Free Zone Corporation (PCFC). PCFCH has investment platforms in the hospitality, retail, real estate and technology sectors. It is the operator, as well as the asset and development manager of the QE2.
A brief history
On September 20 1967, Queen Elizabeth named the QE2 after her mother in the company of Prince Phillip and 30,000 spectators arrived at John Brown’s shipyard on Clydebank in Scotland. On 2 May 1969, she made her maiden transatlantic voyage.
In her lifetime, the QE2 would complete 1,400 voyages, sail some 6 million nautical miles and play gracious host to almost 2.5 million passengers. She would complete 25 tours around the world and, after 39 years, retire in 2008 to join Dubai as a prized and prestigious attraction.
The Queen Elizabeth 2
Katie King, +971-565-263-883
Director of Marketing
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+
Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16 | Pressemelding
HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati
Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30 | Pressemelding
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,